Immunotherapy has revolutionized the area of cancer treatment. Although most immunotherapies now are antibodies targeting membrane checkpoint molecules, there is an increasing demand for small-molecule drugs that address intracellular pathways. The E3 ubiquitin ligase Casitas B cell lymphoma‑b (Cbl-b) has been regarded as a promising intracellular immunotherapy target. Cbl-b regulates the downstream proteins of multiple membrane receptors and co-receptors, restricting the activation of the innate and adaptive immune system. Recently, Cbl-b inhibitors have been reported with promising effects on immune surveillance activation and anti-tumor efficacy. Several molecules have entered phase Ⅰ clinical trials. In this review, the biological rationale of Cbl-b as a promising target for cancer immunotherapy and the latest research progress of Cbl-b are summarized, with special emphasis on the allosteric small-molecule inhibitors of Cbl-b.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2024.117677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells.
Int Immunopharmacol
January 2025
School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Key Laboratory of Anti-inflammatory and Immune Medicines, Ministry of Education, Anhui Medical University, Hefei, Anhui 230032, China; Institute of Clinical Immunology, Anhui Medical University, Hefei, Anhui 230032, China. Electronic address:
Chimeric antigen receptor T (CAR-T) cells represent a promising approach for cancer immunotherapy, yet their efficacy is hindered by immunosuppressive signals in the tumor microenvironment. Casitas B-cell lymphoma protein b (Cbl-b) is a key negative regulator of T cell function. This study investigated whether inhibiting Cbl-b enhances the antitumor activity of human CAR-T cells.
View Article and Find Full Text PDFPotential Therapeutic Benefit of the Selective Inhibitors of Casitas B Cell Lymphoma-b (CBL-B) in Cancer Immunotherapy.
ACS Med Chem Lett
December 2024
PI Health Sciences, 100 Jade Park, Chelsea, Alabama 35043, United State.
The invention in this patent application relates to 1,6-dihydro-7-pyrrolo[2,3-]pyridin-7-one derivatives represented generally by formula 1. These compounds are inhibitors of the E3 ubiquitin ligase, casitas B-lineage lymphoma proto-oncogene-b (CBL-B), and may be useful for the treatment of immunosuppression-associated diseases and disorders such as cancer and chronic viral infections.
View Article and Find Full Text PDFSprouty2 Regulates Endocytosis and Degradation of Fibroblast Growth Factor Receptor 1 in Glioblastoma Cells.
Cells
November 2024
Institute of Neuroanatomy, Medical University of Innsbruck, 6020 Innsbruck, Austria.
The Sprouty (SPRY) proteins are evolutionary conserved modulators of receptor tyrosine kinase (RTK) signaling. SPRY2 inhibits fibroblast growth factor (FGF) signaling, whereas it enhances epidermal growth factor (EGF) signaling through inhibition of EGF receptor (EGFR) endocytosis, ubiquitination, and degradation. In this study, we analyzed the effects of SPRY2 on endocytosis and degradation of FGF receptor 1 (FGFR1) using two human glioblastoma (GBM) cell lines with different endogenous SPRY2 levels.
View Article and Find Full Text PDFFAK activity exacerbates disturbed flow-mediated atherosclerosis via VEGFR2-Cbl-NF-κB signaling.
bioRxiv
December 2024
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294.
Atherosclerosis develops at predictable sites in the vasculature where branch points and curvatures create non-laminar disturbed flow. This disturbed flow causes vascular inflammation by increased endothelial cell (EC) barrier permeability and the expression of inflammatory genes such as vascular cell adhesion molecule-1 (VCAM-1). Vascular endothelial growth factor receptor 2 (VEGFR2) is important for flow-induced EC inflammation; however, there are still some gaps in the signaling pathway.
View Article and Find Full Text PDFInhibition of Cbl-b restores effector functions of human intratumoral NK cells.
J Immunother Cancer
November 2024
Roche Innovation Center, F. Hoffmann-La Roche AG, Roche Pharma Research and Early Development, Basel, Switzerland
Article Synopsis
- T cell-based immunotherapies are effective against cancer but are limited by cancer cells' ability to escape immune detection; recent research is shifting focus to natural killer (NK) cells, which can target tumors directly.
- Newly developed methods have been used to screen for compounds that improve NK cell functionality, particularly in dysfunctional cells found in the tumor microenvironment.
- A promising compound, a C
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!